Header

UZH-Logo

Maintenance Infos

Glypican-3 expression in primary and recurrent ovarian carcinomas


Stadlmann, Sylvia; Gueth, Uwe; Baumhoer, Daniel; Moch, Holger; Terracciano, Luigi; Singer, Gad (2007). Glypican-3 expression in primary and recurrent ovarian carcinomas. International Journal of Gynecological Pathology, 26(3):341-344.

Abstract

The identification of glypican-3 (GPC3) expression in malignant neoplasms is potentially of interest because GPC3 might represent a therapeutic target. Tissue microarrays containing tissue cylinders from 308 patients with ovarian carcinomas were used for an immunohistochemical study. There were 255 serous, 38 endometrioid, and 15 clear-cell carcinomas included. From 76 patients, paired tissue samples of primary serous ovarian carcinomas and their corresponding recurrences after platinum-based chemotherapy were available. Glypican-3 was expressed in a total of 17.9% of ovarian carcinomas and was strongly associated with the clear-cell histotype (P = 0.0001). Glypican-3 expression was not associated with tumor stage. Positive staining for GPC3 was also observed in a significant fraction of recurrent carcinomas but was not particularly associated with chemoresponse. In conclusion, our data show that GPC3 is observed in a significant fraction of primary and corresponding recurrent ovarian carcinomas. Glypican-3 may therefore represent a potential target for (second-line) therapy in ovarian cancer.

Abstract

The identification of glypican-3 (GPC3) expression in malignant neoplasms is potentially of interest because GPC3 might represent a therapeutic target. Tissue microarrays containing tissue cylinders from 308 patients with ovarian carcinomas were used for an immunohistochemical study. There were 255 serous, 38 endometrioid, and 15 clear-cell carcinomas included. From 76 patients, paired tissue samples of primary serous ovarian carcinomas and their corresponding recurrences after platinum-based chemotherapy were available. Glypican-3 was expressed in a total of 17.9% of ovarian carcinomas and was strongly associated with the clear-cell histotype (P = 0.0001). Glypican-3 expression was not associated with tumor stage. Positive staining for GPC3 was also observed in a significant fraction of recurrent carcinomas but was not particularly associated with chemoresponse. In conclusion, our data show that GPC3 is observed in a significant fraction of primary and corresponding recurrent ovarian carcinomas. Glypican-3 may therefore represent a potential target for (second-line) therapy in ovarian cancer.

Statistics

Citations

Dimensions.ai Metrics
38 citations in Web of Science®
47 citations in Scopus®
67 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 24 Jul 2015
0 downloads since 12 months

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:July 2007
Deposited On:24 Jul 2015 10:56
Last Modified:18 Feb 2018 13:17
Publisher:Lippincott Williams & Wilkins
ISSN:0277-1691
OA Status:Closed
Publisher DOI:https://doi.org/10.1097/pgp.0b013e31802d692c
PubMed ID:17581422

Download